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A B S T R A C T
Bovine viral diarrhoea virus (BVDV) is endemic in many countries and vaccines are used as a compo-
nent of control and eradication strategies. Surveillance programmes to detect exposure to BVDV often
incorporate the use of bulk milk (BM) testing for antibodies against BVDV p80 (NS3), but vaccination
can interfere with these results. The aim of this study was to evaluate whether BVDV vaccines would
confound BM testing for speciﬁc antibodies in a nationally representative group of commercial dairy farms
in the Republic of Ireland. A total of 256 commercial dairy herds were included in the statistical analy-
sis. Quarterly BM or serum samples from selected weanling heifers (unvaccinated homeborn youngstock)
were assessed by ELISA for antibodies against the BVDV p80 subunit and whole virus. Wilcoxon rank-
sum and receiver operating characteristic (ROC) analyses were used to examine differences among groups
vaccinated with one of three commercially available inactivated BVDV vaccines. Two of the three vac-
cines showed evidence of interference with ELISA testing of BM samples. ROC analysis highlighted that
one vaccine did not reduce the discriminatory power of the BVDV p80 ELISA for identiﬁcation of herds
with evidence of recent BVDV circulation, when compared with unvaccinated herds; thus, administra-
tion of this vaccine would allow uncomplicated interpretation of BM ELISA test results in vaccinated
seropositive herds. Seasonal differences in BM antibody results were identiﬁed, suggesting that the latter
half of lactation is the most suitable time for sampling dairy herds containing predominantly spring calving
cows. The results of the present study are likely to prove useful in countries allowing vaccination during
or following BVDV eradication, where BM testing is required as part of the surveillance strategy.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Bovine viral diarrhoea virus (BVDV) is endemic in many coun-
tries (Lindberg and Houe, 2005). Control of BVDV involves removing
persistently infected (PI) animals from the herd, ensuring biosecurity
and vaccination of susceptible animals (Moennig et al., 2005). Several
countries, including Ireland1, have initiated eradication pro-
grammes (Ridpath, 2012; Ståhl and Alenius, 2012) andmany of these
countries are close to or have achieved BVDV-free status (Bitsch et al.,
2000; Valle et al., 2005; Presi et al., 2011).
Detection of BVDV-speciﬁc antibodies in bulkmilk (BM) samples
is routinely used to determine herd health status, prior to intro-
duction of BVDVcontrolmeasures and for surveillancepurposes after
implementation of a control programme (Houe et al., 2006). BM
analysis is often combinedwith selective (spot) testing of young stock
for serum antibodies against BVDV, to determine whether there is
evidence of recent virus circulation (RVC) in a herd, since BM results
often reﬂect historical rather than current antibody responses (Mars
and Van Maanen, 2005; Laureyns et al., 2010).
Use of a BVDV vaccine is a confounding factor when interpret-
ing test results for immunoassays designed to detect antibodies
against BVDV, since it can be diﬃcult to differentiate vaccinated from
infected animals (DIVA). This issue has led some Scandinavian coun-
tries to prohibit the use of BVDV vaccines during, and subsequent
to, BVDV eradication (Greiser-Wilke et al., 2003; Barrett et al., 2011).
However, vaccination is often a feature of BVDV control and erad-
ication strategies in high seroprevalence countries, such as Ireland
(Makoschey et al., 2007; Barrett et al., 2011), thereby restricting the
usefulness of BM testing as a surveillance tool.
Previous studies have examined the impact of vaccination against
BVDV on antibody testing under controlled conditions (Graham et al.,
2003; Makoschey et al., 2007; Raue et al., 2011). Small scale ﬁeld
studies have been conducted on a single Dutch farm (Kuijk et al.,
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2008), on two (Álvarez et al., 2012) and three (González et al., 2014)
Spanish dairy farms, and on 34 UK farms, themajority of which used
a vaccine that is no longer commercially available (Booth et al., 2013).
These studies investigated whether the use of a p80 (NS3) subunit
ELISA has the potential to allow differentiation between infected
animals and those receiving inactivated BVDV vaccines.
Such differentiation might be possible, since administration of
an inactivated form of the virus should lead to limited exposure of
the immune system to the p80 non-structural protein, which is pro-
duced predominantly during viral replication (Graham et al., 2003;
González et al., 2014). Although some of the inactivated BVDV vac-
cines evaluated seemed to generate an antibody response that was
not detected with the p80 ELISA, more recent studies have sug-
gested that DIVA is not straightforward (Raue et al., 2011; González
et al., 2014), but might be possible at the herd level, with the use
of BM samples rather than individual sera (Álvarez et al., 2012).
The aim of the present studywas to undertake a large scale, farm-
based study of the impact of BVDV vaccination on BM testing in a
high seroprevalence region. A commercially available BVDV p80 ELISA
was evaluated for use in BM testing in a nationally representative
group of dairy farms in the Republic of Ireland, where three dif-
ferent commercial BVDV vaccines were being administered.
Materials and methods
Study population and sample collection
A detailed description of the sample population used in the present study has
been provided by O’Doherty et al. (2013). Stratiﬁed proportional sampling, based
on herd size and geographical location, was used to randomly select and invite farmers
on 500 Herdplus farms from the Irish Cattle Breeding Federation (ICBF) database2
to participate in the study without incentives. A total of 312 commercial dairy farms
were subsequently recruited.
BM samples were submitted from each herd on four occasions (March, June,
August and November) in 2009. Farms were visited from October 2009 to January
2010 to sample weanling heifers (unvaccinated homeborn youngstock). Blood samples
were obtained by coccygeal venepuncture from 20% of the weanling group, with a
minimum of ﬁve heifers sampled per farm. Serum samples were obtained follow-
ing centrifugation of clotted blood samples for testing by ELISA. Where possible, only
weanlings >270 days of age were sampled, although this was not achieved on all
farms. Accurate weanling age, based on calf registration data, was accessed from the
ICBF database.
The vaccination status of each herd was determined by questionnaire. Herds for
which there was not a complete set of four BM samples (n = 3), which did not return
the vaccination questionnaire (n = 4), which did not supply a vaccine brand name
(n = 19), which recorded positive weanlings <270 days of age (n = 22) or for which
weanling ages were unavailable (n = 8) were excluded from the study; of the 312
farms initially recruited, a total of 256 herds were eligible for statistical analyses.
Sample analysis
BM samples at each time point were analysed at an accredited laboratory (Na-
tional Milk Laboratories) using a BVDV p80 blocking ELISA (Institut Pourquier),
demonstrating a sensitivity (Se) of 95.0% and speciﬁcity (Sp) of 97.7% for BM (Beaudeau
et al., 2001). Heifer serum samples were also tested using this assay (Se 97.6%, Sp
97.3%). On the basis of optical density at 450 nm (OD450), results are reported as %
inhibition, i.e. 1 – (OD450, of the analysed sample/mean OD450 of the negative
control) × 100, with cut-off values for positivity of ≥55% and >60% inhibition applied
for BM and serum, respectively.
BM samples submitted in March and August were also tested in an approved
laboratory (Enfer Diagnostics) using an indirect BVDV ELISA against whole virus
antigen (IDEXX Laboratories; Se 96.3%, Sp 99.5%) (Hashemi Tabar et al., 2011). Results
are reported as S/P values, i.e. (OD450 of sample – OD450 of negative control)/(mean
OD450 of positive control – OD450 of negative control), with the positive cut-off value
for BM samples set at 0.2.
Herd classiﬁcation
Herds were classiﬁed on the basis of geographical density (high density dairy;
low density dairy), enterprise type (dairy livestock; mixed livestock) and herd size
(31–65 cows; 66–99 cows; >99 cows). Calving data from the ICBF database were used
to determine the calving season of each herd (spring calving; not spring calving, i.e.
spring–autumn, SA; year-round, YR), as described by O’Doherty et al. (2013). Vac-
cination status (vaccinated; unvaccinated) was determined by questionnaire,
requesting date of vaccination and product used (Bovilis BVD, MSD Animal Health;
Bovidec, Novartis Animal Health; PregSure BVD, Zoetis Animal Health).
Herds were also classiﬁed in terms of the presence of positive test results in un-
vaccinated weanlings. Herds having at least one weanling >270 days of age with
detectable antibodies against BVDVwere classiﬁed as RVC (Houe, 1994; Handel et al.,
2011; Løken and Nyberg, 2013); herds not recording any seropositive weanlings were
classiﬁed as no recent virus circulation (NRVC). Herds containing seropositive young
stock <270 days of age were excluded from this part of the analysis, due to poten-
tial interference from maternally derived antibodies (MDA).
Statistical analysis
Microsoft Excel (MS Oﬃce 2010) was used for descriptive statistics and graphi-
cal representations. Statistical analyses including Wilcoxon rank sum analysis,
generalised estimating equations and receiver operating characteristic (ROC) anal-
ysis were performed using Stata (Version 12). Power calculations were performed
using G*Power (Version 3.1.9).
Eight datasets were constructed, consisting of varying combinations of unvac-
cinated and vaccinated RVC and NRVC herds. The normality of each dataset was
assessed using the Shapiro–Wilk normality test and visually using ladder of powers
histograms constructed in Stata (Version 12). Differences between vaccinated and
unvaccinated herds of varying BVDV circulation status (RVC and NRVC) were ex-
amined using non-parametric Wilcoxon rank sum analysis. ROC analysis was
completed to examine the discriminating power (area under the curve, AUC) of average
BM results (classiﬁcation variable) in identifying RVC herds (reference variable) in
the unvaccinated herd datasets and vaccine brand datasets. An ROC analysis will yield
AUC values between 0.5 and 1.0; the closer the value to 1.0, the greater the dis-
criminating power of BM results in distinguishing RVC from NRVC herds (Greiner
et al., 2000). Vaccinated and unvaccinated herds were assumed to have equal levels
of seroprevalence, based on existing data in Ireland (Cowley et al., 2012). Three ROC
analyses were completed to determine the Se and Sp of potential BVDV p80 ELISA
positive cut-off values in groups incorporating unvaccinated herds and herds vac-
cinated with Bovilis BVD (n = 144), Bovidec (n = 175) or PregSure BVD (n = 151).
Generalised estimating equations (GEEs) were used to investigate seasonal pat-
terns in BM test results across vaccination status and vaccine brand. Herdwas included
as a repeated measure, a Gaussian distribution was assumed and an exchangeable
correlation structure was applied. Associations between vaccine brand and explan-
atory variables, i.e. region, herd size, calving-season, mean of quarterly BM test results
(positive vs. negative) and evidence of RVC (at least one positive weanling vs. no
positive weanlings) were examined by multinomial logistic regression. As a ﬁrst step,
explanatory variables recording P values ≤0.15 in a univariate analysis were in-
cluded in the multivariate model. A manual backwards elimination with a forward
step was completed for all models, with variables recording P values ≤0.05 being
maintained in the ﬁnal model. All second level interactions were also examined.
Results
The distribution of study herds across region, herd size, calving
season and type of enterprise is shown in Appendix: Supplementary
Table S1. Herd BM, RVC and vaccination status are shown in
Appendix: Supplementary Table S2. In the Pourquier p80 ELISA, ≥55%
inhibition results were recorded in BM from 94/118 (79.7%) un-
vaccinated herds, indicating a high prevalence of seroconversion
against the BVDV p80 antigen from natural viral infection. Of the
vaccinated herds suitable for statistical analysis (n = 149), 68/149
(45.6%) used Bovidec, 44/149 (29.5%) used PregSure BVD and 37/149
(24.8%) used Bovilis BVD. The most common time of year to vac-
cinate against BVDV was January to April, when 153/190 (80.5%)
of herds were vaccinated. A total of 2171 serum samples fromwean-
lings (mean age 291 days, range 109–549 days) were analysed, with
543/2171 (25.0%) testing seropositive for BVDV; at least one sero-
positive weanling >270 days of age was identiﬁed in 87/256 (33.9%)
study herds.
Quarterly median BVDV p80 ELISA BM results for vaccinated and
unvaccinated herds across vaccine brand over time are shown in
Fig. 1. Corresponding Wilcoxon rank-sum z and P values are shown
in Table 1. Using the Pourquier p80 ELISA, there were signiﬁcant
increases in median percentage BM ELISA inhibition values over the
entire lactation in NRVC herds vaccinated with Bovidec (10.8–24.1%;
P < 0.01) or PregSure BVD (14.0–26.4%; P < 0.01), but not in NRVC2 See: http://www.icbf.com/?page_id = 56 (accessed 23 October 2014).
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herds vaccinated with Bovilis BVD (0.46–10.9%; P values 0.14–0.55
at different sampling dates), compared to unvaccinated NRVC herds
(Fig. 1A; Table 1).
NRVC herds vaccinated with Bovilis BVD had signiﬁcantly lower
median BM ELISA percentage inhibition values at each sampling time
point than unvaccinated RVC herds (March: P = 0.02; June: P = 0.009;
August: P = 0.003; November: P = 0.002), while NRVC herds vacci-
natedwith Bovidec recorded no signiﬁcant difference (March: P = 0.7;
June: P = 0.15; August: P = 0.8; November: P = 0.8). PregSure BVD
vaccinated NRVC herds recorded elevated % inhibition values com-
pared to unvaccinated RVC herds inMarch (P = 0.035), June (P = 0.001)
and August (P = 0.008), with no signiﬁcant difference (P = 0.16) re-
corded in November (Table 1). There was no signiﬁcant difference
in ELISA values in herds with evidence of RVC, regardless of vac-
cination status or vaccine brand administered (Fig. 1B; Table 1).
There was a signiﬁcant increase (P < 0.01) in whole virus antigen
ELISA values in BM fromNRVC herds vaccinatedwith any of the three
BVDV vaccine brands in comparison with NRVC unvaccinated herds;
animals vaccinated with the PregSure BVD vaccine had the highest
values (Fig. 2; Table 1). Power calculations relating to the most per-
tinent between-group comparisons are outlined in Appendix:
Supplementary Tables S3 and S4. With the exception of the March
comparison between Bovilis BVD NRVC and unvaccinated RVC herds,
sample sizes were of suﬃcient power (≥0.8) to detect reported
between-group differences.
ROC analysis of BM and spot test results on serum samples from
weanling heifers in unvaccinated herds yielded an AUC of 0.78.
Bovilis BVD vaccinated herds recorded similar powers of discrim-
ination between RVC and NRVC herds, yielding an AUC of 0.77
(P = 0.91; Fig 3A; Table 2). Herds vaccinated with Bovidec or PregSure
BVD yielded AUC values of 0.50 and 0.55, respectively, indicating
that RVC and NRVC herds could not be distinguished using these
vaccines (Figs. 3B, C; Table 2). A p80 ELISA percentage inhibition
positive cut-off value for BM samples between 83.3% (Se 71.4%, Sp
72.6%) and 86.5% (Se 65.3%, Sp 81.0%) correctly classiﬁed >70% of
unvaccinated and Bovilis BVD vaccinated herds (n = 144).
Examination of the effect of seasonality on ELISA test results in
unvaccinated herds showed signiﬁcantly increased ELISA % inhibition
Table 1
Range of Wilcoxon rank sum z and P values for vaccinated and unvaccinated recent
virus circulation (RVC) and no recent virus circulation (NRVC) herds across month
of sampling (March to November).
Vaccine Pourquier BVDV
p80 subunit
IDEXX whole
BVDV antigena
z value rangeb P value rangeb z value rangeb P value rangeb
Vaccinated NRVC vs.
unvaccinated NRVC
Vaccinated NRVC vs.
unvaccinated NRVC
Bovidec −4.96 to −3.58 <0.01 −5.12 to −5.07 <0.01
Bovilis BVD −1.49 to −0.59 0.1–0.6 −3.62 to −2.96 <0.01
PregSure
BVD
−6.51 to −4.46 <0.01 −6.16 to −5.16 <0.01
Vaccinated NRVC vs.
unvaccinated RVC
Vaccinated NRVC vs.
unvaccinated RVC
Bovidec −1.44 to 0.23 0.15–0.8 −0.92 to 0.48 0.4–0.6
Bovilis BVD 2.38–3.15 <0.05 0.16–1.52 0.1–0.9
PregSure
BVD
−3.47 to −1.39 <0.01–0.2 −3.96 to −3.78 <0.01
Vaccinated RVC vs.
unvaccinated RVC
Vaccinated RVC vs.
unvaccinated RVC
Bovidec −0.96 to −0.01 0.3–1.0 −1.37 to −0.51 0.2–0.6
Bovilis BVD −1.34 to 0.14 0.2–0.9 −1.37 to −1.79 0.07–0.2
PregSure
BVD
−2.53 to −0.65 0.01–0.5 −3.94 to −2.99 <0.01
a Data represent March and August samples and were analysed only as a means
of verifying vaccine administration. These data were not used for seasonal analy-
ses.
b All z and P values for each month of sampling are within the ranges listed. Where
a single ﬁgure is listed, i.e. P < 0.001, all data points yielded the same value.
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Fig. 1. Quarterly median bovine viral diarrhoea virus (BVDV) p80 ELISA test results
(% inhibition) across (A) no recent virus circulation (NRVC) vaccinated (Bovidec, Bovilis
BVD or PregSure BVD) and NRVC unvaccinated herds, and (B) recent virus circula-
tion (RVC) vaccinated and RVC unvaccinated herds.
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Fig. 2. Median bovine viral diarrhoea virus (BVDV) antibody S/P values measured
in bulk milk (BM) using the IDEXX whole virus antigen ELISA in unvaccinated and
vaccinated no recent virus circulation (NRVC) herds in March and August 2009.
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values in the latter half of the year, regardless of infection status.
Seasonality of test results in vaccinated herds was more variable
(see Appendix: Supplementary Table S5).
A number of associations were highlighted between explana-
tory variables and the use of each vaccine brand (Table 3). An
interaction between explanatory variables, region and RVC high-
lighted that, compared to herds vaccinated with Bovilis BVD, herds
vaccinated with Bovidec were more likely to record positive wean-
lings in a high dairy density region than a low density region
(P = 0.03). In addition, relative to herds vaccinated with Bovilis BVD,
mixed enterprise herds were less likely to use PregSure BVD than
herds managing dairy stock only (relative ratio, RR = 0.26; P < 0.01).
Discussion
Vaccination has a role to play in the control of BVDV infection,
once PI animals have been identiﬁed and removed from the herd
(Makoschey et al., 2007; Ståhl and Alenius, 2012). Although the im-
munological protection offered by BVDV vaccines is limited when
naïve cattle are exposed to PI animals shedding large amounts of
virus (Ståhl and Alenius, 2012), vaccination can be a valuable tool
in protection against clinical disease. However, the use of vaccines
can compromise surveillance strategies based on the use of sero-
logical assays to determine if there has been exposure to BVDV in
herds. In the present study, an inactivated vaccine was identiﬁed
that could be used alongside a BVDV subunit ELISA to DIVA.
In the present study, a relatively large proportion of spring calving
herds were recruited. Such herds have a relatively stable compo-
sition over a lactation period and animals are vaccinated at a similar
time of the year. These factors potentially reduce the ﬂuctuations
Table 2
Bulk milk p80 ELISA receiver operating characteristic (ROC) analyses of unvacci-
nated (UV) and vaccinated (Bovilis BVD, Bovidec, PregSure BVD) herds for
differentiation of herds with recent virus circulation (RVC).
Vaccine status n AUCa Standard error 95% Conﬁdence
interval
P value
UV 107 0.78 0.05 0.69–0.86
Bovilis BVD 37 0.77 0.09 0.59–0.94
UV vs. Bovilis BVD 0.91
Bovidec 68 0.50 0.07 0.36–0.64
UV vs. Bovidec <0.01
PregSure BVD 44 0.55 0.11 0.33–0.75
UV vs. PregSure BVD 0.05
a ROC area under the curve.
Table 3
Multinomial logistic regression analysis of vaccine brand use across region, herd size,
calving season and type of livestock enterprise.
Explanatory variables in comparison of
vaccine brands
Relative
ratio
95%
Conﬁdence
interval
P value
Bovidec vs. Bovilis BVD
Mixed vs. dairy only 0.49 0.21–1.20 0.1
Bulk milk positive vs. negativea 1.49 0.39–5.63 0.6
High density vs. low density*NRVC vs. RVC 9.77 1.23–77.45 0.03
PregSure BVD vs. Bovilis BVD
Mixed vs. dairy onlyb 0.26 0.09–0.67 <0.01
Bulk milk positive vs. negativea 8.49 0.88–8.81 0.06
High density vs. low density*NRVC vs. RVC 4.57 0.44–47.10 0.2
PregSure BVD vs. Bovidec
Mixed vs. dairy only 0.52 0.23–1.16 0.1
Bulk milk positive vs. negativea 5.67 0.66–48.60 0.1
High density vs. low density*NRVC vs. RVC 0.47 0.08–2.83 0.4
Explanatory variables included in the model were Region, Recent infection,
Region × Recent infection, Enterprise and Bulk milk status (Model P < 0.01). * Inter-
action between explanatory variables ‘Region’ and ‘Recent infection’.
a Bulk milk positive and negative is based on themean of quarterly bulk milk ELISA
results.
b Relative to herds vaccinating with Bovilis BVD, herds vaccinating with PregSure
BVD were less likely (relative ratio = 0.26) to operate a mixed livestock enterprise
compared to a dairy only herd.
B
C
A
Fig. 3. Receiver operating characteristic (ROC) curves comparing discriminatory power
of BM testing to identify recent virus circulation (RVC) herds in unvaccinated (UV)
and herds vaccinated with (A) Bovidec, (B) Bovilis BVD and (C) PregSure BVD.
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in BM test results reported by Booth et al. (2013), thereby allow-
ing more deﬁnitive conclusions to be drawn. The high BVDV
seroprevalences reported in Irish dairy herds in the current study
(80%) and by Cowley et al. (2012) (98%) should minimise differences
in BVDV status between vaccinated and unvaccinated groups, thereby
allowing meaningful comparisons across study groups. A poten-
tial weakness of the present study is that only vaccines administered
in 2009 were recorded and the impact of prior vaccine use on results
cannot be assessed.
In an ideal situation, vaccines should be an integral compo-
nent of a BVDV eradication and surveillance programme, provided
vaccination has minimal interference with BM antibody testing.
Certain conditions should be met, before a particular vaccine would
be considered to be suitable for use in BVDV control programmes.
Themedian percentage inhibition value of unvaccinated NRVC herds
should not differ from that of vaccinated NRVC herds using the p80
ELISA, i.e. administration of the vaccine should not result in sig-
niﬁcantly increased levels of p80 antibodies. The median percentage
inhibition value of unvaccinated RVC herds should be signiﬁ-
cantly greater than that of vaccinated NRVC herds using the p80
ELISA, i.e. it should be possible to distinguish vaccinated herds from
those with evidence of recent viral transmission and infection. The
median S/P value (whole virus ELISA) of a vaccinated group should
not be signiﬁcantly lower than that of other vaccine groups
examined, i.e. the vaccine should be administered correctly and
should induce a BVDV antibody response. Finally, ROC analysis of
BM and spot testing of vaccinated herds should not be signiﬁ-
cantly different from unvaccinated herds, i.e. AUC values in vaccinated
and unvaccinated herds should indicate comparable power
(AUC > 0.5; P > 0.05) in distinguishing RVC from NRVC herds.
Under ﬁeld conditions in a high seroprevalence region, Bovilis
BVD was the only one of three vaccines that satisﬁed the stated cri-
teria, when used in conjunctionwith the Pourquier p80 ELISA. Bovilis
BVD vaccinated herds did not differ signiﬁcantly from unvacci-
nated herds in the parameters included in the statistical analysis.
Additionally, ROC analysis of unvaccinated and Bovilis BVD vacci-
nated herds yielded a similar BM positive cut-off value for detecting
RVC herds to that suggested by Thobokwe et al. (2004) (80% inhi-
bition) in a study in New Zealand dairy herds, in a production system
similar to that in Ireland.
In contrast, Bovidec and PregSure BVD appear to elicit BVDV p80-
speciﬁc antibody responses, limiting their usefulness in surveillance
programmes, where a large proportion of seropositive herds are
present. It should be noted that the antibody response to Bovilis
BVDmay be transient (Álvarez et al., 2012); furthermore, all farmers
in the current study administered a single annual booster dose to
their herds, contrasting with the three dose regime outlined by
Álvarez et al. (2012). Further research is required to better charac-
terise the serological response to inactivated BVD vaccines
immediately post-vaccination and how this might affect BM testing.
Inappropriate vaccine use or vaccine failure could have inﬂu-
enced the study outcome. However, it is considered to be unlikely
that this would be biased towards any particular vaccine brand. The
BM antibody test results against whole BVDV were not signiﬁ-
cantly different between Bovidec and Bovilis BVD vaccines, suggesting
that the differences observed in the Pourquier p80 ELISA were spe-
ciﬁc to the vaccine brand. The elevated antibody reactivity against
whole BVDV observed with the PregSure BVD vaccine is possibly
due to increased immunogenicity associated with the speciﬁc ad-
juvant used in this vaccine (Demasius et al., 2013). The PregSure
BVD vaccine has recently beenwithdrawn, due to links with neonatal
pancytopenia in calves (Deutskens et al., 2011; Euler et al., 2013).
Seasonal variation in BM test results was evaluated, since it has
been reported that BVDV antibody levels inmilk are inversely related
to the amount of milk produced (Niskanen et al., 1989). The ma-
jority of herds in the present study calved in the spring, with peak
lactation occurring 9 weeks post-calving (Quinn et al., 2005); a sig-
niﬁcant increase in antibody values was recorded in unvaccinated
herds in the latter half of the year, as anticipated. This indicates that
autumnmight be a more suitable period for sampling unvaccinated
herds, to avoid false negative results. Although signiﬁcant differ-
ences between sampling times were also recorded in vaccinated
herds, none were of a magnitude to warrant suggesting an optimal
time of year for BM sampling in vaccinated herds. The variation in
individual animal responses to vaccination, as outlined in previ-
ous studies (Raue et al., 2011), highlights the usefulness of herd level
BM testing, which avoids issues with sampling at different times
post-vaccination.
Further research is required into farm level risk factors, which
might account for the increased likelihood of seropositive wean-
lings on farms using Bovidec compared to Bovilis BVD. It is possible
that Bovilis BVD performs better in reducing the levels of new/
recent infection in dairy systems or, alternatively, that farmers
experiencing issues with active BVDV infection are more likely to
select Bovidec. Similarly, herds vaccinatedwith PregSure BVD tended
to bemore likely to record a positivemean annual BM p80 test result,
which again may indicate increased use of this vaccine in herds ex-
periencing problems with BVDV, rather than inferior vaccine
performance. The signiﬁcantly elevated values recorded in PregSure
BVD vaccinated herds for both BVDV p80 and whole virus antigen
ELISAs may be the main contributing factor. These ﬁndings should
be investigated further to allow evidence-based recommenda-
tions with regard to BVDV vaccine use.
Conclusions
Administration of Bovilis BVD results inminimal interferencewith
BM testing for antibodies against BVDV using the Pourquier p80
ELISA. Therefore, use of this vaccine is compatible with BVDV erad-
ication and surveillance programmes.
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